9 results about "Vaccine delivery" patented technology

A method for inducing an immune response in an individual to treat or prevent a disease or condition is provided, the method comprising administering a vaccine comprising lipid nanoparticles encapsulating nucleic acids encoding antigen proteins, peptides, or fragments thereof, a neutral lipid content of 30% to 70% molar ratio, sterols or derivatives thereof, and 5 to 50% molar ratio of ionizable cationic amino lipids, and a hydrophilic polymer-lipid conjugate present at a lipid content of 0% to 5% molar ratio, wherein administration of the lipid nanoparticles results in an immune response in an individual against the antigen protein, peptide, or fragment thereof expressed by mRNA, wherein each % molar ratio of lipid content relative to the total lipid content of the lipid nanoparticles is measured. This disclosure also provides vaccine compositions and the use of such compositions in inducing an immune response in an individual.

An adjuvant polypeptide, a nano-carrier and application of the nano-carrier in vaccine adjuvant, the present application relates to the field of vaccine.The present application solves the problems of poor antigen compatibility, lack of targeting, low delivery efficiency and insufficient preparation stability of traditional adjuvant.The amino acid sequence of the adjuvant polypeptide Adp is VLGKLAKVAI.The nano-carrier is prepared from the adjuvant polypeptide and antigen.The nano-carrier is prepared by mixing the adjuvant polypeptide and antigen through in-situ radical polymerization.The application of the nano-carrier in vaccine adjuvant.The present application screens a new vaccine adjuvant by bioinformatics method, so that it has the abilities of dendritic cell targeting and intracellular STING pathway activation, thereby enhancing the cross-presentation of antigen.Based on this, the new adjuvant is coupled with monomer, and an intelligent vaccine delivery system is constructed by in-situ polymerization method, so as to realize the efficient delivery of tumor cell membrane protein antigen and improve the immunotherapy effect of tumor vaccine.

This disclosure relates to extracellular vesicles (EVs), such as exosomes, comprising a payload (e.g., an antigen, adjuvant, and / or immunomodulator) and / or a targeting portion. Methods for generating EVs (e.g., exosomes) and methods for using EVs (e.g., exosomes) to treat and / or prevent diseases or conditions, such as cancer, graft-versus-host disease (GvHD), autoimmune diseases, infectious diseases, or fibrotic diseases, are also provided herein.

The present application relates to a kind of preparation method and application of HPV recombinant protein therapeutic vaccine, belong to biological medicine technical field, the preparation method of the HPV recombinant protein therapeutic vaccine described includes: a plurality of complex lipid nanoparticles prepared by lipid are simultaneously wrapped and delivered HPV16HPV E6E7 recombinant protein antigen and nucleic acid TLR agonist adjuvant molecule.This application is beneficial to the recombinant protein therapeutic vaccine prepared to induce strong T cell immune response to HPV16E6E7 antigen, kill the cervical cancer cell infected by HPV.In addition, unlike the lipid nanoparticle (LNP) of mRNA vaccine delivery, there is no cation or ionizable lipid in the formula, significantly higher than mRNA vaccine in safety, with greater advantage than mRNA therapeutic vaccine, and low toxicity and side effects, vaccine effect is stable.

This invention discloses a dual-targeting DNA vaccine delivery system based on calcium phosphate lipid nanoparticles, belonging to the field of biomedicine. The delivery system comprises calcium phosphate containing histone H1 and an HPV E6 / E7 fusion gene plasmid, and a lipid bilayer membrane of DSPE-PEG-2000-Mannose. This system achieves targeted uptake by dendritic cells through mannose modification and relies on histone H1-mediated DNA nuclear transport. The dual targeting significantly enhances antigen expression efficiency. In vitro and in vivo experiments have demonstrated that this delivery system exhibits good biocompatibility and high stability, effectively activating antigen-specific T-cell immune responses, and possesses both HPV infection prevention and cervical cancer treatment effects, providing a new strategy for cervical cancer prevention and treatment.

Disclosed herein are compositions comprising a hydrogel scaffold, methods of generating a hydrogel scaffold, and systems for and methods of using the hydrogel scaffold to produce biologically active molecules.

This invention discloses a stabilized emulsion, its preparation method, and its uses. The invention stabilizes the emulsion using aluminum hydroxide microgels. The stabilized emulsion comprises an oil phase, an aqueous phase, and a composite stabilizer adsorbed at the oil-water interface or dispersed in the aqueous phase. Adding charged particles that interact with the aluminum hydroxide microgels to the stabilizer further enhances the emulsion's stability and immune response. The stabilized emulsion of this invention can be used as an oil-emulsion adjuvant, exhibiting uniform particle size, good dispersibility, good stability, and tunable properties. It can simultaneously activate humoral and cellular immune responses and can be used as a vaccine adjuvant or in vaccine delivery systems for preventative and therapeutic vaccines.

The application discloses a vaccine dispensing system, belongs to the technical field of automatic vaccine dispensing, and solves the problem that the prior art vaccine dispensing system is inconvenient to upgrade and transform on the basis of the existing vaccination hall. The vaccine dispensing system comprises a vaccination table, a vaccine delivery channel, a central cold storage and a feeding device; a plurality of vaccination tables are connected in sequence, the vaccination table and the central cold storage are connected through the vaccine delivery channel, and the feeding device can enter the vaccination table and the central cold storage through the vaccine delivery channel. The vaccine dispensing system provided by the application has a vaccination table similar in appearance to an existing office table, guarantees comfort, can improve vaccination efficiency without affecting the leg space of medical staff, and since the vaccine delivery channel is arranged in the vaccination table, the existing vaccine vaccination hall does not need to be removed and reconstructed, and the existing vaccine vaccination hall can be conveniently upgraded and constructed.

Provided herein are compositions including epitopes for HBHA, Rv3351c, and ESAT6, and optionally one or both of Rv1490 and HUPB; nucleic acid(s) encoding the same, and combinations thereof. The epitopes are present on one or more polypeptides, optionally one or more fusion protein. In some forms, the epitope(s) for HBHA are present on a HBHA polypeptide. In some forms, the epitope(s) for Rv3351c and the epitope(s) for ESAT6 are present on a Rv3351c-ESAT6 fusion protein. In some forms, the one or more of the epitopes are package in or on a particle, optionally nanoparticles. Exemplary nanoparticles are formed of wax, PLGA, etc. In some forms, the composition further includes a hydrogel-based vaccine delivery platform. In some forms, the composition includes an adjuvant such as glucopyranosyl lipid A (GLA) and / or CpG. Also provided are methods of using the compositions for increasing an immune response.